Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen Macarena (13)

2019

  1. Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort

    Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 55-64

  2. Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort

    Liver International, Vol. 39, Núm. 1, pp. 90-97

  3. Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort

    PLoS ONE, Vol. 14, Núm. 8

2016

  1. Indicadores asistenciales en pacientes con fibrilación auricular: evaluación del manejo de los problemas clínicos y de las diferencias por sexo

    Revista Espanola de Cardiologia, Vol. 69, Núm. 4, pp. 384-391

2015

  1. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis

    World Journal of Gastroenterology, Vol. 21, Núm. 30, pp. 9163-9174

  2. Perfil clínico y seguimiento de los pacientes con hepatitis C crónica en hospitales españoles: Estudio disHCovery

    Revista Espanola de Quimioterapia, Vol. 28, Núm. 3, pp. 145-153

2014

  1. Valor de la genética en la era de la terapia triple frente al virus de la hepatitis C

    Gastroenterologia y Hepatologia, Vol. 37, Núm. 7, pp. 427-437

2009

  1. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin

    Hepatology, Vol. 50, Núm. 6, pp. 1702-1708

2008

  1. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C

    Journal of Hepatology, Vol. 48, Núm. 5, pp. 721-727

2007

  1. Treatment of chronic he1patitis C genotype 1 with peginterferon- α2a (40 kDa) plus ribavirin under routine clinical practice in Spain: Early prediction of sustained virological response rate

    Alimentary Pharmacology and Therapeutics, Vol. 25, Núm. 8, pp. 899-906

2005

  1. Drug-induced liver injury: An analysis of 461 incidences submitted to the Spanish registry over a 10-year period

    Gastroenterology, Vol. 129, Núm. 2, pp. 512-521

2004

  1. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease

    Hepatology, Vol. 39, Núm. 6, pp. 1603-1612

2003

  1. Comparative study of the efficacy of an induction dose of interferon-α2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C

    Journal of Viral Hepatitis, Vol. 10, Núm. 6, pp. 437-445